Agios Pharma Q3 revenue beats expectations

Agios Pharmaceuticals

30/10/2025 10:50

Overview

Agios Q3 2025 product revenue of $12.9 mln beats analyst expectations

Net loss of $103.4 mln in Q3 2025, compared to net income last year

Agios preparing for potential PYRUKYND U.S. launch in thalassemia by 2026

Outlook

Agios expects U.S. commercial launch of PYRUKYND for thalassemia in 2026

European Commission decision on PYRUKYND expected by early 2026

Topline results from RISE UP Phase 3 trial expected by year-end

Result Driver

THALASSEMIA APPROVAL - FDA extended PDUFA date for PYRUKYND sNDA to Dec 7, 2025 due to REMS request

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Revenue
Beat
$12.88 mln
$10.50 mln (8 Analysts)
Q3 Net Income
-$103.43 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Agios Pharmaceuticals Inc is $51.00, about 17.7% above its October 29 closing price of $41.96

Press Release: ID:nGNXKF4HF

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)